Figure S2 from Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

Supplementary Figure S2. Relative abundance of peripheral immune cells. (A-D) Boxplots illustrating the differences in immune cell scores between baseline and post-rintatolimod (A), between progressive disease and stable disease patients at baseline (B), between progressive disease and stable disease patients post-rintatolimod (C), and delta change between progressive disease and stable disease patients (D). The x-axis displays the different immune cell subsets, and the y-axis displays the immune cell score or delta immune cell score (upper right).